David A. Siegel Autolus Therapeutics PLC Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 164,700 shares of AUTL stock, worth $395,280. This represents 0.0% of its overall portfolio holdings.

Number of Shares

164,700

Previous 333,400 50.6%

Holding current value

$395,280

Previous $783,000 67.43%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.55 - $2.68 $261,485 - $452,116	-168,700 Reduced 50.6%	164,700 $255,000
Q4 2024 Feb 14, 2025	BUY	$2.18 - $4.8 $33,572 - $73,920	15,400 Added 4.84%	333,400 $783,000
Q3 2024 Nov 14, 2024	BUY	$3.38 - $4.69 $207,194 - $287,497	61,300 Added 23.88%	318,000 $1.15 Million
Q2 2024 Aug 14, 2024	BUY	$3.33 - $5.68 $751,248 - $1.28 Million	225,600 Added 725.4%	256,700 $893,000
Q1 2024 May 15, 2024	BUY	$5.39 - $7.29 $8,084 - $10,935	1,500 Added 5.07%	31,100 $198,000
Q4 2023 Feb 14, 2024	BUY	$2.13 - $6.63 $9,585 - $29,835	4,500 Added 17.93%	29,600 $190,000
Q3 2023 Nov 14, 2023	SELL	$2.32 - $3.36 $3,016 - $4,368	-1,300 Reduced 4.92%	25,100 $58,000
Q2 2023 Aug 14, 2023	BUY	$1.64 - $3.21 $20,828 - $40,767	12,700 Added 92.7%	26,400 $62,000
Q1 2023 May 15, 2023	BUY	$1.75 - $2.25 $23,975 - $30,825	13,700 New	13,700 $25,000
Q2 2021 Aug 16, 2021	SELL	$4.78 - $7.96 $66,442 - $110,644	-13,900 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.49 - $9.36 $76,311 - $130,103	13,900 New	13,900 $80,000

Others Institutions Holding AUTL

# of Institutions

Shares Held

163M

Call Options Held

Put Options Held

88.3K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $218M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account